Clinical trials: Infliximab, open to volunteers
Crohn's Disease (CD)
Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study
Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections (biologics) or a liquid-only diet using specialised…
- Trial name
- BIOPIC-Kids (NCT07522528)
- Testing
- enteral nutrition
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Crohn Disease
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
Crohn's disease (CD) is a chronic inflammatory bowel disease. CD pathogenesis remains poorly understood but involves an inappropriate immune response toward an unbalanced gut microbiota in predisposed hosts.
- Trial name
- MIRACLE (NCT04997733)
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis
A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
A subcutaneous formulation of infliximab CT-P13 (Remsima, Celltrion) has been approved for clinical use in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) after demonstration of pharmacokinetic (PK) non-inferiority…
- Trial name
- NCT07120152
- Testing
- Subcutaneous infliximab CT-P13 Remsima®SC
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Erwin Dreesen
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Healthy Volunteer
A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants
- Trial name
- NCT07776782
- Testing
- MT-201
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Mirador Therapeutics, Inc.